Takeda begins US distribution of narcolepsy type 1 drug Orzeyful
The therapy is an oral orexin receptor 2 agonist, formulated to target the orexin deficiency that causes the chronic neurological condition. Following approval by the US Food and
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.
The partnership links real-world product adoption analytics with commercial modelling to assist companies in making clinical development, investment, and commercialisation choices. The companies will combine their respective analytical